These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 19914467)

  • 21. High expression of DNA repair pathways is associated with metastasis in melanoma patients.
    Kauffmann A; Rosselli F; Lazar V; Winnepenninckx V; Mansuet-Lupo A; Dessen P; van den Oord JJ; Spatz A; Sarasin A
    Oncogene; 2008 Jan; 27(5):565-73. PubMed ID: 17891185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic tissue markers in melanoma.
    Moore DA; Pringle JH; Saldanha GS
    Histopathology; 2012 Apr; 60(5):679-89. PubMed ID: 21880059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression profiling of primary cutaneous melanoma.
    Winnepenninckx V; Van den Oord JJ
    Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What genomics has taught me about melanocytic neoplasms.
    Leboit PE
    G Ital Dermatol Venereol; 2012 Jun; 147(3):239-49. PubMed ID: 22648325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden.
    Schramm SJ; Li SS; Jayaswal V; Fung DC; Campain AE; Pang CN; Scolyer RA; Yang YH; Mann GJ; Wilkins MR
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):708-22. PubMed ID: 23738911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The classification of cutaneous melanoma.
    Duncan LM
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):501-13, ix. PubMed ID: 19464599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microarray comparative genomic hybridization detection of copy number changes in desmoplastic melanoma and malignant peripheral nerve sheath tumor.
    Pryor JG; Brown-Kipphut BA; Iqbal A; Scott GA
    Am J Dermatopathol; 2011 Dec; 33(8):780-5. PubMed ID: 21785329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of mutant p53 in melanoma.
    Stretch JR; Gatter KC; Ralfkiaer E; Lane DP; Harris AL
    Cancer Res; 1991 Nov; 51(21):5976-9. PubMed ID: 1933861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How, and from which cell sources, do nevi really develop?
    Grichnik JM; Ross AL; Schneider SL; Sanchez MI; Eller MS; Hatzistergos KE
    Exp Dermatol; 2014 May; 23(5):310-3. PubMed ID: 24588745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors.
    Gonzalgo ML; Bender CM; You EH; Glendening JM; Flores JF; Walker GJ; Hayward NK; Jones PA; Fountain JW
    Cancer Res; 1997 Dec; 57(23):5336-47. PubMed ID: 9393758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential diagnosis of melanocytic lesions and molecular biology.
    Dummer R; Kerl K; Mihic D; Kamarachev J
    Arch Dermatol; 2011 Feb; 147(2):232-3. PubMed ID: 21339451
    [No Abstract]   [Full Text] [Related]  

  • 32. Main clues in the pathologic diagnosis of melanoma: is molecular genetics helping?
    Ferrara G; Senetta R; Paglierani M; Massi D
    Dermatol Ther; 2012; 25(5):423-31. PubMed ID: 23046021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and genetic mechanisms in melanoma.
    Gruber F; Kastelan M; Brajac I; Saftić M; Peharda V; Cabrijan L; Stanić Zgombić Z; Simonić E
    Coll Antropol; 2008 Oct; 32 Suppl 2():147-52. PubMed ID: 19138018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and functional validation of therapeutic targets for malignant melanoma.
    Gremel G; Rafferty M; Lau TY; Gallagher WM
    Crit Rev Oncol Hematol; 2009 Dec; 72(3):194-214. PubMed ID: 19328713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic testing in hereditary melanoma.
    Tsao H; Niendorf K
    J Am Acad Dermatol; 2004 Nov; 51(5):803-8. PubMed ID: 15523363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic techniques for primary cutaneous melanoma.
    Lien MH; Sondak VK
    G Ital Dermatol Venereol; 2009 Apr; 144(2):187-94. PubMed ID: 19357625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors.
    Winnepenninckx V; van den Oord JJ
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1611-31. PubMed ID: 18020928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melanoma: do we need a hatchet or a scalpel?
    Shackleton MJ; Quintana E; Fullen DR; Sabel MS; Johnson TM
    Arch Dermatol; 2009 Mar; 145(3):307-8. PubMed ID: 19289763
    [No Abstract]   [Full Text] [Related]  

  • 39. EGFR in melanoma: clinical significance and potential therapeutic target.
    Boone B; Jacobs K; Ferdinande L; Taildeman J; Lambert J; Peeters M; Bracke M; Pauwels P; Brochez L
    J Cutan Pathol; 2011 Jun; 38(6):492-502. PubMed ID: 21352258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.
    Goldstein AM; Liu L; Shennan MG; Hogg D; Tucker MA; Struewing JP
    Br J Cancer; 2001 Aug; 85(4):527-30. PubMed ID: 11506491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.